Learning Objectives:

• 20 min session with at least 10 min for Q&A.
• Discuss the evidence for transfusion thresholds in patients with MDS.
• Apply strategies to optimize transfusion support in patients with MDS.

Learning Objectives:

• To review the components of geriatric assessment as it applies to oncology.
• To understand the value of specific geriatric domains to MDS in terms of prognostication, treatment modification, and co-management.

Learning Objectives:

• To outline how to identify patients/families with likely germline predisposition to MDS or other hematopoietic malignancies.
• To use molecular profiling data from leukemia cells to identify patients with likely germline predisposition who do not have a strong personal or family history of cancer.
• To outline the best practices for performing germline genetic testing for predisposition risk for hematopoietic malignancies.

Learning Objectives:

• Learn the potential for immunotherapy responses in MDS compared with AML.
• Discuss potential cellular immunotherapy targets in MDS.
• Review the progress of cellular immunotherapy in MDS.

Learning Objectives:

• Review transfusional iron overload (IOL) in MDS patients.
• Demonstrate a new website that contains key information on managing transfusional IOL toxicity and strategies to minimize iron load.
• Walk through a case to determine recommendations for management.
• Review key evidence that iron reduction in MDS is beneficial.
• Discuss IOL-induced oxidative stress in MDS.
• Review new data on IOL from the Canadian MDS Patient Registry.

Learning Objectives:

• The participant will understand biological and prognostic differences between de novo and therapy-related MDS.
• The participant will learn about the available data on the efficacy of established and novel therapies in therapy-related MDS.
• As a result of attending this presentation, the participant will be able to assign therapy-related MDS patients to appropriate therapies.

Learning Objectives:

• The participant will understand biological and prognostic differences between de novo and therapy-related MDS.
• The participant will learn about the available data on the efficacy of established and novel therapies in therapy-related MDS.
• As a result of attending this presentation, the participant will be able to assign therapy-related MDS patients to appropriate therapies.

The EUMDS Registry has identified novel meaningful outcome indicators and clinical endpoints, and reliable measures of response to available health care interventions.

Learning Objectives:

• The combination of innovative clinical, molecular, and statistical techniques with prospectively collected real-world data may identify meaningful novel dynamic outcome indicators and new clinical endpoints for patients usually excluded from randomized clinical trials.
• Available evidence derived from EUMDS Registry data suggests that in most patients with LR-MDS, the risk of death is not related to disease progression and is mainly attributable to non-leukemic death.
• A proportion of these lower-risk MDS patients have prolonged survival that precludes to design clinical trials adopting overall survival as a primary endpoint. These challenges may bias assessment of the effectiveness and appropriate use of the available interventions in this patient population.